A feasibility study of using biodegradable magnesium alloy in glaucoma drainage device
|
摘要
Technological advances in glaucoma have challenged the traditional treatment paradigm. Historically incisional surgery has been used in cases of advanced disease and/or uncontrolled intraocular pressures resistant to medical or laser interventions. More recently, perhaps due to advancements in imaging, surgery has been suggested to be beneficial earlier in the treatment paradigm. Despite these trends, surgical manipulation of the tissues and unpredictability of wound healing continue to result in surgical failure. Magnesium is an essential element for human body and plays a critically important role in maintaining the functional and structural integrity of several tissues, including the eye. Due to several of its advantageous properties such as non-toxicity, biodegradability, and high biological compatibility, magnesium alloy has attracted great attention as a novel biomaterial. Biodegradable cardiovascular stents made of magnesium alloy have already been introduced into clinical practice. The purpose of this review is to determine if bioabsorbable magnesium alloys can be utilized as a promising candidate for the development of a new generation of glaucoma surgical assistive devices.
Technological advances in glaucoma have challenged the traditional treatment paradigm. Historically incisional surgery has been used in cases of advanced disease and/or uncontrolled intraocular pressures resistant to medical or laser interventions. More recently, perhaps due to advancements in imaging, surgery has been suggested to be beneficial earlier in the treatment paradigm. Despite these trends, surgical manipulation of the tissues and unpredictability of wound healing continue to result in surgical failure. Magnesium is an essential element for human body and plays a critically important role in maintaining the functional and structural integrity of several tissues, including the eye. Due to several of its advantageous properties such as non-toxicity, biodegradability, and high biological compatibility, magnesium alloy has attracted great attention as a novel biomaterial. Biodegradable cardiovascular stents made of magnesium alloy have already been introduced into clinical practice. The purpose of this review is to determine if bioabsorbable magnesium alloys can be utilized as a promising candidate for the development of a new generation of glaucoma surgical assistive devices.
Technological advances in glaucoma have challenged the traditional treatment paradigm. Historically incisional surgery has been used in cases of advanced disease and/or uncontrolled intraocular pressures resistant to medical or laser interventions. More recently, perhaps due to advancements in imaging, surgery has been suggested to be beneficial earlier in the treatment paradigm. Despite these trends, surgical manipulation of the tissues and unpredictability of wound healing continue to result in surgical failure. Magnesium is an essential element for human body and plays a critically important role in maintaining the functional and structural integrity of several tissues, including the eye. Due to several of its advantageous properties such as non-toxicity, biodegradability, and high biological compatibility, magnesium alloy has attracted great attention as a novel biomaterial. Biodegradable cardiovascular stents made of magnesium alloy have already been introduced into clinical practice. The purpose of this review is to determine if bioabsorbable magnesium alloys can be utilized as a promising candidate for the development of a new generation of glaucoma surgical assistive devices.
引文
1 Mubagwa K,Gwanyanya A,Zakharov S,Macianskiene R.Regulation of cation channels in cardiac and smooth muscle cells by intracellular magnesium.Arch Biochem Biophys 2007;458(1):73-89.
2 Ellahioui Y,Prashar S,Gomez-Ruiz S.A short overview on the biomedical applications of silica,alumina and calcium phosphate-based nanostructured materials.Curr Med Chem 2016;23(39):4450-4467.
3 Okuma T.Magnesium and bone strength.Nutrition 2001;17(7-8):679-680.
4 Orchard TS,Larson JC,Alghothani N,Bout-Tabaku S,Cauley JA,Chen Z,La Croix AZ,Wactawski-Wende J,Jackson RD.Magnesium intake,bone mineral density,and fractures:results from the Women's Health Initiative Observational Study.Am J Clin Nutr 2014;99(4):926-933.
5 Farsinejad-Marj M,Saneei P,Esmaillzadeh A.Dietary magnesium intake,bone mineral density and risk of fracture:a systematic review and meta-analysis.Osteoporosis Int 2016;27(4):1389-1399.
6 Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference I.The national academies collection:reports funded by national institutes of health.Washington(DC):National Academies Press(US);1997.
7 Takeda R,Nakamura T.Effects of high magnesium intake on bone mineral status and lipid metabolism in rats.J Nutr Sci Vitaminol(Tokyo)2008;54(1):66-75.
8 O'Brien B,Carroll W.The evolution of cardiovascular stent materials and surfaces in response to clinical drivers:a review.Acta Biomater 2009;5(4):945-958.
9 Mani G,Feldman MD,Patel D,Agrawal CM.Coronary stents:a materials perspective.Biomaterials 2007;28(9):1689-1710.
10 Saris NE,Mervaala E,Karppanen H,Khawaja JA,Lewenstam A.Magnesium.An update on physiological,clinical and analytical aspects.Clin Chim Acta 2000;294(1-2):1-26.
11 Vormann J.Magnesium:nutrition and metabolism.Mol Aspects Med2003;24(1-3):27-37.
12 Quigley HA.Number of people with glaucoma worldwide.Br J Ophthalmol 1996;80(5):389-393.
13 Atreides SP,Skuta GL,Reynolds AC.Wound healing modulation in glaucoma filtering surgery.Int Ophthalmol Clin 2004;44(2):61-106.
14 Cordeiro MF,Bhattacharya SS,Schultz GS,Khaw PT.TGF-beta1,-beta2,and-beta3 in vitro:biphasic effects on Tenon's fibroblast contraction,proliferation,and migration.Invest Ophthalmol Vis Sci 2000;41(3):756-763.
15 Huan ZG,Leeflang MA,Zhou J,Fratila-Apachitei LE,Duszczyk J.In vitro degradation behavior and cytocompatibility of Mg-Zn-Zr alloys.J Mater Sci Mater Med 2010;21(9):2623-2635.
16 Hu CY,Matsuo H,Tomita G,Suzuki Y,Araie M,Shirato S,Tanaka S.Clinical characteristics and leakage of functioning blebs after trabeculectomy with mitomycin-C in primary glaucoma patients.Ophthalmology 2003;110(2):345-352.
17 Lehmann OJ,Bunce C,Matheson MM,Maurino V,Khaw PT,Wormald R,Barton K.Risk factors for development of post-trabeculectomy endophthalmitis.Br J Ophthalmol 2000;84(12):1349-1353.
18 Grillo CA,Alvarez F,Fernandez Lorenzo de Mele MA.Degradation of bioabsorbable Mg-based alloys:Assessment of the effects of insoluble corrosion products and joint effects of alloying components on mammalian cells.Mater Sci Eng C Mater Biol Appl 2016;58:372-380.
19 Walker J,Shadanbaz S,Woodfield TB,Staiger MP,Dias GJ.Magnesium biomaterials for orthopedic application:a review from a biological perspective.J Biomed Mater Res B Appl Biomater 2014;102(6):1316-1331.
20 Hanzi AC,Gerber I,Schinhammer M,Loffler JF,Uggowitzer PJ.On the in vitro and in vivo degradation performance and biological response of new biodegradable Mg-Y-Zn alloys.Acta Biomater 2010;6(5):1824-1833.
21 Lambotte A.The classic.Contribution to conservative surgery of the injured hand.By Dr.A.Lambotte.1928.Clin Orthop Relat Res 1987;(214):4-6.
22 Mc Bride ED.Absorbable metal in bone surgery.J Am Med Assoc1938;111(27):2464-2467.
23 Troitskii VV,Tsitrin DN.The resorbing metallic alloy“Osteosinthezit”as material for fastening broken bone.Khirurgiia 1944;8:41-44.
24 Znamenskii MS.Metallic osteosynthesis by means of an apparatus made of resorbing metal.Khirurgiia 1945;12:60-63.
25 Zberg B,Uggowitzer PJ,Loffler JF.Mg Zn Ca glasses without clinically observable hydrogen evolution for biodegradable implants.Nat Mater2009;8(11):887-891.
26 Gu X,Zheng Y,Cheng Y,Zhong S,Xi T.In vitro corrosion and biocompatibility of binary magnesium alloys.Biomaterials 2009;30(4):484-498.
27 Janning C,Willbold E,Vogt C,Nellesen J,Meyer-Lindenberg A,Windhagen H,Thorey F,Witte F.Magnesium hydroxide temporarily enhancing osteoblast activity and decreasing the osteoclast number in peri-implant bone remodelling.Acta Biomater 2010;6(5):1861-1868.
28 Yang JX,Cui FZ,Lee IS,Zhang Y,Yin QS,Xia H,Yang SX.In vivo biocompatibility and degradation behavior of Mg alloy coated by calcium phosphate in a rabbit model.J Biomater Appl 2012;27(2):153-164.
29 Witte F,Ulrich H,Palm C,Willbold E.Biodegradable magnesium scaffolds:Part II:peri-implant bone remodeling.J Biomed Mater Res A2007;81(3):757-765.
30 Witte F,Ulrich H,Rudert M,Willbold E.Biodegradable magnesium scaffolds:Part 1:appropriate inflammatory response.J Biomed Mater Res A 2007;81(3):748-756.
31 Witte F,Feyerabend F,Maier P,Fischer J,Stormer M,Blawert C,Dietzel W,Hort N.Biodegradable magnesium-hydroxyapatite metal matrix composites.Biomaterials 2007;28(13):2163-2174.
32 Okazaki M.New type scaffold biomaterials with magnesium accelerating osteoblast adhesion and bone formation.J Oral Tissue Eng2004;1(1):31-40.
33 Zreiqat H,Evans P,Howlett CR.Effect of surface chemical modification of bioceramic on phenotype of human bone-derived cells.J Biomed Mater Res 1999;44(4):389-396.
34 Hunt J,Heggarty D.Application of microscopic methods for the detection of cell attachment to polymers.Methods Mol Biol 2004;238:207-216.
35 Luscher TF,Steffel J,Eberli FR,Joner M,Nakazawa G,Tanner FC,Virmani R.Drug-eluting stent and coronary thrombosis:biological mechanisms and clinical implications.Circulation 2007;115(8):1051-1058.
36 Bertrand OF,Sipehia R,Mongrain R,Rodes J,Tardif JC,Bilodeau L,Cote G,Bourassa MG.Biocompatibility aspects of new stent technology.J Am Coll Cardiol 1998;32(3):562-571.
37 Heublein B,Rohde R,Kaese V,Niemeyer M,Hartung W,Haverich A.Biocorrosion of magnesium alloys:a new principle in cardiovascular implant technology?Heart 2003;89(6):651-656.
38 Waksman R,Pakala R,Kuchulakanti PK,Baffour R,Hellinga D,Seabron R,Tio FO,Wittchow E,Hartwig S,Harder C,Rohde R,Heublein B,Andreae A,Waldmann KH,Haverich A.Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries.Catheter Cardiovasc Interv 2006;68(4):607-617;discussion 618-619.
39 Zartner P,Cesnjevar R,Singer H,Weyand M.First successful implantation of a biodegradable metal stent into the left pulmonary artery of a preterm baby.Catheter Cardiovasc Interv 2005;66(4):590-594.
40 Di Mario C,Griffiths H,Goktekin O,Peeters N,Verbist J,Bosiers M,Deloose K,Heublein B,Rohde R,Kasese V,Ilsley C,Erbel R.Drugeluting bioabsorbable magnesium stent.J Interv Cardiol 2004;17(6):391-395.
41 Schranz D,Zartner P,Michel-Behnke I,Akinturk H.Bioabsorbable metal stents for percutaneous treatment of critical recoarctation of the aorta in a newborn.Catheter Cardiovasc Interv 2006;67(5):671-673.
42 Mulla A,Massey KL,Kalra J.Vitreous humor biochemical constituents:evaluation of between-eye differences.Am J Forensic Med Pathol 2005;26(2):146-149.
43 George GA,Heaton FW.Changes in cellular composition during magnesium deficiency.Biochem J 1975;152(3):609-615.
44 Agarwal R,Iezhitsa L,Agarwal P.Pathogenetic role of magnesium deficiency in ophthalmic diseases.Biometals 2013.[Epub ahead of print]
45 Hatwal A,Gujral AS,Bhatia RP,Agrawal JK,Bajpai HS.Association of hypomagnesemia with diabetic retinopathy.Acta Ophthalmol(Copenh)1989;67(6):714-716.
46 Mishima S.Clinical pharmacokinetics of the eye.Proctor lecture.Invest Ophthalmol Vis Sci 1981;21(4):504-541.
47 Kirkpatrick H.The use of magnesium sulphate as a local application in inflammation of the conjunctiva and cornea.Br J Ophthalmol 1920;4(6):281.
48 Bachman WG,Wilson G.Essential ions for maintenance of the corneal epithelial surface.Invest Ophthalmol Vis Sci 1985;26(11):1484-1488.
49 Hogan ZS,Brown KL,Ishola A,Gatimu J,Flucker L,Huff JW.Effects of divalent cations on bovine corneal stromal swelling rates.Curr Eye Res2008;33(8):677-682.
50 Gong H,Amemiya T,Takaya K.Retinal changes in magnesiumdeficient rats.Exp Eye Res 2001;72(1):23-32.
51 Thalasselis A.The possible relationship between keratoconus and magnesium deficiency.Ophthalmic Physiol Opt 2005;25(1):7-12.
52 Andreassen TT,Simonsen AH,Oxlund H.Biomechanical properties of keratoconus and normal corneas.Exp Eye Res 1980;31(4):435-441.
53 Aktekin M,Sargon MF,Cakar P,Celik HH,Firat E.Ultrastructure of the cornea epithelium in keratoconus.Okajimas Folia Anat Jpn 1998;75(1):45-53.
54 Sawaguchi S,Fukuchi T,Abe H,Kaiya T,Sugar J,Yue BY.Threedimensional scanning electron microscopic study of keratoconus corneas.Arch Ophthalmol 1998;116(1):62-68.
55 Pouliquen Y,Graf B,Hamada R,Giraud JP,Offret G.Fibrocytes in keratoconus.Morphological aspect and modification of the extra-cellular space.Study with light and electron microscopy.Arch Ophtalmol Rev Gen Ophtalmol 1972;32(8):571-586.
56 Dilsiz N,Olcucu A,Atas M.Determination of calcium,sodium,potassium and magnesium concentrations in human senile cataractous lenses.Cell Biochem Funct 2000;18(4):259-262.
57 Agarwal R,Iezhitsa I,Agarwal P,Spasov A.Magnesium deficiency:does it have a role to play in cataractogenesis?Exp Eye Res 2012;101:82-89.
58 Agarwal R,Iezhitsa I,Awaludin NA,Ahmad Fisol NF,Bakar NS,Agarwal P,Abdul Rahman TH,Spasov A,Ozerov A,Mohamed Ahmed Salama MS,Mohd Ismail N.Effects of magnesium taurate on the onset and progression of galactose-induced experimental cataract:in vivo and in vitro evaluation.Exp Eye Res 2013;110:35-43.
59 Nagai N,Fukuhata T,Ito Y.Effect of magnesium deficiency on intracellular ATP levels in human lens epithelial cells.Biol Pharm Bull2007;30(1):6-10.
60 Nagai N,Ito Y,Inomata M,Shumiya S,Tai H,Hataguchi Y,Nakagawa K.Delay of cataract development in the Shumiya cataract rat by the administration of drinking water containing high concentration of magnesium ion.Biol Pharm Bull 2006;29(6):1234-1238.
61 Agarwal R,Iezhitsa IN,Agarwal P,Spasov AA.Mechanisms of cataractogenesis in the presence of magnesium deficiency.Magnes Res2013;26(1):2-8.
62 Kao CL,Chou CK,Tsai DC,Hsu WM,Liu JH,Wang CS,Lin JC,Wu CC,Peng CH,Chang CJ,Kao CL,Chiou SH.Nitric oxide levels in the aqueous humor in cataract patients.J Cataract Refract Surg2002;28(3):507-512.
63 Ornek K,Karel F,Buyukbingol Z.May nitric oxide molecule have a role in the pathogenesis of human cataract?Exp Eye Res 2003;76(1):23-27.
64 Retamal MA,Yin S,Altenberg GA,Reuss L.Modulation of Cx46hemichannels by nitric oxide.Am J Physiol Cell Physiol 2009;296(6):C1356-1363.
65 Carafoli E.The Ca2+pump of the plasma membrane.J Biol Chem 1992;267(4):2115-2118.
66 Hulsman CA,Vingerling JR,Hofman A,Witteman JC,de Jong PT.Blood pressure,arterial stiffness,and open-angle glaucoma:the Rotterdam study.Arch Ophthalmol 2007;125(6):805-812.
67 Bonomi L,Marchini G,Marraffa M,Bernardi P,Morbio R,Varotto A.Vascular risk factors for primary open angle glaucoma:the EgnaNeumarkt Study.Ophthalmology 2000;107(7):1287-1293.
68 Leske MC,Heijl A,Hyman L,Bengtsson B,Dong L,Yang Z.Predictors of long-term progression in the early manifest glaucoma trial.Ophthalmology 2007;114(11):1965-1972.
69 Wang M,Tashiro M,Berlin JR.Regulation of L-type calcium current by intracellular magnesium in rat cardiac myocytes.J Physiol2004;555(Pt 2):383-396.
70 Howarth FC,Levi AJ.Internal free magnesium modulates the voltage dependence of contraction and Ca transient in rabbit ventricular myocytes.Pflugers Arch 1998;435(5):687-698.
71 Ishiguro S,Matsuyama T,Sakaguchi H,Nishio A.Ex vivo study of the increased sensitivity to NO of endothelium-denuded thoracic aortas isolated from dietary magnesium-deficient rats.Magnes Res1997;10(1):21-31.
72 Laurant P,Touyz RM.Physiological and pathophysiological role of magnesium in the cardiovascular system:implications in hypertension.J Hypertens 2000;18(9):1177-1191.
73 Teragawa H,Kato M,Yamagata T,Matsuura H,Kajiyama G.Magnesium causes nitric oxide independent coronary artery vasodilation in humans.Heart 2001;86(2):212-216.
74 Barbagallo M,Dominguez LJ,Galioto A,Pineo A,Belvedere M.Oral magnesium supplementation improves vascular function in elderly diabetic patients.Magnes Res 2010;23(3):131-137.
75 Soltani N,Keshavarz M,Sohanaki H,Zahedi Asl S,Dehpour AR.Relaxatory effect of magnesium on mesenteric vascular beds differs from normal and streptozotocin induced diabetic rats.Eur J Pharmacol2005;508(1-3):177-181.
76 Kumar AR,Kurup PA.Inhibition of membrane Na+-K+ATPase activity:a common pathway in central nervous system disorders.J Assoc Physicians India 2002;50:400-406.
77 Sugiyama T,Moriya S,Oku H,Azuma I.Association of endothelin-1with normal tension glaucoma:clinical and fundamental studies.Surv Ophthalmol 1995;39 Suppl 1:S49-S56.
78 Kaiser HJ,Flammer J,Graf T,Stümpfig D.Systemic blood pressure in glaucoma patients.Graefes Arch Clin Exp ophthalmol 1993;231(12):677-680.
79 Winterkorn JM.The influence of magnesium on visual field and peripheral vasospasm in glaucoma.Surv Ophthalmol 1995;40(1):83-84.
80 Mc Menimen KA,Dougherty DA,Lester HA,Petersson EJ.Probing the Mg2+blockade site of an N-methyl-D-aspartate(NMDA)receptor with unnatural amino acid mutagenesis.ACS Chem Biol 2006;1(4):227-234.
81 Mark LP,Prost RW,Ulmer JL,Smith MM,Daniels DL,Strottmann JM,Brown WD,Hacein-Bey L.Pictorial review of glutamate excitotoxicity:fundamental concepts for neuroimaging.AJNR Am J Neuroradiol 2001;22(10):1813-1824.
82 Decollogne S,Tomas A,Lecerf C,Adamowicz E,Seman M.NMDA receptor complex blockade by oral administration of magnesium:comparison with MK-801.Pharmacol Biochem Behav 1997;58(1):261-268.
83 Lambuk L,Jafri AJ,Arfuzir NN,Iezhitsa I,Agarwal R,Rozali KN,Agarwal P,Bakar NS,Kutty MK,Yusof AP,Krasilnikova A,Spasov A,Ozerov A,Ismail NM.Neuroprotective effect of magnesium acetyltaurate against NMDA-induced excitotoxicity in rat retina.Neurotox Res2017;31(1):31-45.
84 Carafoli E.Calcium-a universal carrier of biological signals.Delivered on 3 July 2003 at the Special FEBS Meeting in Brussels.FEBS J2005;272(5):1073-1089.
85 Blaylock RL.Food additive excitotoxins and degenerative brain disorders.Med Sentinel 1999;4:212-215.
86 Sun MH,Pang JH,Chen SL,Han WH,Ho TC,Chen KJ,Kao LY,Lin KK,Tsao YP.Retinal protection from acute glaucoma-induced ischemiareperfusion injury through pharmacologic induction of heme oxygenase-1.Invest Ophthalmol Vis Sci 2010;51(9):4798-4808.
87 Lipton SA,Choi YB,Pan ZH,Lei SZ,Chen HS,Sucher NJ,Loscalzo J,Singel DJ,Stamler JS.A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds.Nature 1993;364(6438):626-632.
88 Suschek CV,Kolb H,Kolb-Bachofen VV.Effects of magnesium dobesilate on nitric oxide synthase activity in endothelial cells.In J Angiol1999;8(5):21-24.
89 Sun X,Mei Y,Tong E.Effect of magnesium on nitric oxide synthase of neurons in cortex during early period of cerebral ischemia.J Tongji Med Univ 2000;20(1):13-15,42.
90 Gaspar AZ,Gasser P,Flammer J.The influence of magnesium on visual field and peripheral vasospasm in glaucoma.Ophthalmologica1995;209(1):11-13.
91 Aydin B,Onol M,Hondur A,Kaya MG,Ozdemir H,Cengel A,Hasanreisoglu B.The effect of oral magnesium therapy on visual field and ocular blood flow in normotensive glaucoma.Eur J Ophthalmol2010;20(1):131-135.
92 Troncoso MU.Cyclodialysis with insertion of a metal implant in the treatment of glaucoma:a preliminary report.Arch Ophthalmol 1940;23(2):270-297.
93 Hoff PHB.Use of troncoso's magnesium implant in cyclodialysis for relief of glaucoma:observations in two cases.Arch Ophthalmol1945;33(5):404-405.
94 Moravej M,Mantovani D.Biodegradable metals for cardiovascular stent application:interests and new opportunities.Int J Mol Sci 2011;12(7):4250-4270.
95 Staiger MP,Pietak AM,Huadmai J,Dias G.Magnesium and its alloys as orthopedic biomaterials:a review.Biomaterials 2006;27(9):1728-1734.
96 Zeng R,Dietzel W,Witte F,Hort N,Blawert C.Progress and challenge for magnesium alloys as biomaterials.Adv Eng Mater 2008;10(8):B3-B14.
97 Joner M,Finn AV,Farb A,Mont EK,Kolodgie FD,Ladich E,Kutys R,Skorija K,Gold HK,Virmani R.Pathology of drug-eluting stents in humans:delayed healing and late thrombotic risk.J Am Coll Crdiol2006;48(1):193-202.
98 Nebeker JR,Virmani R,Bennett CL,Hoffman JM,Samore MH,Alvarez J,Davidson CJ,Mc Koy JM,Raisch DW,Whisenant BK,Yarnold PR,Belknap SM,West DP,Gage JE,Morse RE,Gligoric G,Davidson L,Feldman MD.Hypersensitivity cases associated with drug-eluting coronary stents:a review of available cases from the Research on Adverse Drug Events and Reports(RADAR)project.J Am Coll Crdiol 2006;47(1):175-181.
99 Nordmann AJ,Briel M,Bucher HC.Mortality in randomized controlled trials comparing drug-eluting vs bare metal stents in coronary artery disease:a meta-analysis.Eur Heart J 2006;27(23):2784-2814.
100 Hofma SH,van der Giessen WJ,van Dalen BM,Lemos PA,Mc Fadden EP,Sianos G,Ligthart JM,van Essen D,de Feyter PJ,Serruys PW.Indication of long-term endothelial dysfunction after sirolimuseluting stent implantation.Eur Heart J 2006;27(2):166-170.
101 Erbel R,Di Mario C,Bartunek J,Bonnier J,de Bruyne B,Eberli FR,Erne P,Haude M,Heublein B,Horrigan M,Ilsley C,Bose D,Koolen J,Luscher TF,Weissman N,Waksman R.Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents:a prospective,non-randomised multicentre trial.Lancet 2007;369(9576):1869-1875.
2 Ellahioui Y,Prashar S,Gomez-Ruiz S.A short overview on the biomedical applications of silica,alumina and calcium phosphate-based nanostructured materials.Curr Med Chem 2016;23(39):4450-4467.
3 Okuma T.Magnesium and bone strength.Nutrition 2001;17(7-8):679-680.
4 Orchard TS,Larson JC,Alghothani N,Bout-Tabaku S,Cauley JA,Chen Z,La Croix AZ,Wactawski-Wende J,Jackson RD.Magnesium intake,bone mineral density,and fractures:results from the Women's Health Initiative Observational Study.Am J Clin Nutr 2014;99(4):926-933.
5 Farsinejad-Marj M,Saneei P,Esmaillzadeh A.Dietary magnesium intake,bone mineral density and risk of fracture:a systematic review and meta-analysis.Osteoporosis Int 2016;27(4):1389-1399.
6 Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference I.The national academies collection:reports funded by national institutes of health.Washington(DC):National Academies Press(US);1997.
7 Takeda R,Nakamura T.Effects of high magnesium intake on bone mineral status and lipid metabolism in rats.J Nutr Sci Vitaminol(Tokyo)2008;54(1):66-75.
8 O'Brien B,Carroll W.The evolution of cardiovascular stent materials and surfaces in response to clinical drivers:a review.Acta Biomater 2009;5(4):945-958.
9 Mani G,Feldman MD,Patel D,Agrawal CM.Coronary stents:a materials perspective.Biomaterials 2007;28(9):1689-1710.
10 Saris NE,Mervaala E,Karppanen H,Khawaja JA,Lewenstam A.Magnesium.An update on physiological,clinical and analytical aspects.Clin Chim Acta 2000;294(1-2):1-26.
11 Vormann J.Magnesium:nutrition and metabolism.Mol Aspects Med2003;24(1-3):27-37.
12 Quigley HA.Number of people with glaucoma worldwide.Br J Ophthalmol 1996;80(5):389-393.
13 Atreides SP,Skuta GL,Reynolds AC.Wound healing modulation in glaucoma filtering surgery.Int Ophthalmol Clin 2004;44(2):61-106.
14 Cordeiro MF,Bhattacharya SS,Schultz GS,Khaw PT.TGF-beta1,-beta2,and-beta3 in vitro:biphasic effects on Tenon's fibroblast contraction,proliferation,and migration.Invest Ophthalmol Vis Sci 2000;41(3):756-763.
15 Huan ZG,Leeflang MA,Zhou J,Fratila-Apachitei LE,Duszczyk J.In vitro degradation behavior and cytocompatibility of Mg-Zn-Zr alloys.J Mater Sci Mater Med 2010;21(9):2623-2635.
16 Hu CY,Matsuo H,Tomita G,Suzuki Y,Araie M,Shirato S,Tanaka S.Clinical characteristics and leakage of functioning blebs after trabeculectomy with mitomycin-C in primary glaucoma patients.Ophthalmology 2003;110(2):345-352.
17 Lehmann OJ,Bunce C,Matheson MM,Maurino V,Khaw PT,Wormald R,Barton K.Risk factors for development of post-trabeculectomy endophthalmitis.Br J Ophthalmol 2000;84(12):1349-1353.
18 Grillo CA,Alvarez F,Fernandez Lorenzo de Mele MA.Degradation of bioabsorbable Mg-based alloys:Assessment of the effects of insoluble corrosion products and joint effects of alloying components on mammalian cells.Mater Sci Eng C Mater Biol Appl 2016;58:372-380.
19 Walker J,Shadanbaz S,Woodfield TB,Staiger MP,Dias GJ.Magnesium biomaterials for orthopedic application:a review from a biological perspective.J Biomed Mater Res B Appl Biomater 2014;102(6):1316-1331.
20 Hanzi AC,Gerber I,Schinhammer M,Loffler JF,Uggowitzer PJ.On the in vitro and in vivo degradation performance and biological response of new biodegradable Mg-Y-Zn alloys.Acta Biomater 2010;6(5):1824-1833.
21 Lambotte A.The classic.Contribution to conservative surgery of the injured hand.By Dr.A.Lambotte.1928.Clin Orthop Relat Res 1987;(214):4-6.
22 Mc Bride ED.Absorbable metal in bone surgery.J Am Med Assoc1938;111(27):2464-2467.
23 Troitskii VV,Tsitrin DN.The resorbing metallic alloy“Osteosinthezit”as material for fastening broken bone.Khirurgiia 1944;8:41-44.
24 Znamenskii MS.Metallic osteosynthesis by means of an apparatus made of resorbing metal.Khirurgiia 1945;12:60-63.
25 Zberg B,Uggowitzer PJ,Loffler JF.Mg Zn Ca glasses without clinically observable hydrogen evolution for biodegradable implants.Nat Mater2009;8(11):887-891.
26 Gu X,Zheng Y,Cheng Y,Zhong S,Xi T.In vitro corrosion and biocompatibility of binary magnesium alloys.Biomaterials 2009;30(4):484-498.
27 Janning C,Willbold E,Vogt C,Nellesen J,Meyer-Lindenberg A,Windhagen H,Thorey F,Witte F.Magnesium hydroxide temporarily enhancing osteoblast activity and decreasing the osteoclast number in peri-implant bone remodelling.Acta Biomater 2010;6(5):1861-1868.
28 Yang JX,Cui FZ,Lee IS,Zhang Y,Yin QS,Xia H,Yang SX.In vivo biocompatibility and degradation behavior of Mg alloy coated by calcium phosphate in a rabbit model.J Biomater Appl 2012;27(2):153-164.
29 Witte F,Ulrich H,Palm C,Willbold E.Biodegradable magnesium scaffolds:Part II:peri-implant bone remodeling.J Biomed Mater Res A2007;81(3):757-765.
30 Witte F,Ulrich H,Rudert M,Willbold E.Biodegradable magnesium scaffolds:Part 1:appropriate inflammatory response.J Biomed Mater Res A 2007;81(3):748-756.
31 Witte F,Feyerabend F,Maier P,Fischer J,Stormer M,Blawert C,Dietzel W,Hort N.Biodegradable magnesium-hydroxyapatite metal matrix composites.Biomaterials 2007;28(13):2163-2174.
32 Okazaki M.New type scaffold biomaterials with magnesium accelerating osteoblast adhesion and bone formation.J Oral Tissue Eng2004;1(1):31-40.
33 Zreiqat H,Evans P,Howlett CR.Effect of surface chemical modification of bioceramic on phenotype of human bone-derived cells.J Biomed Mater Res 1999;44(4):389-396.
34 Hunt J,Heggarty D.Application of microscopic methods for the detection of cell attachment to polymers.Methods Mol Biol 2004;238:207-216.
35 Luscher TF,Steffel J,Eberli FR,Joner M,Nakazawa G,Tanner FC,Virmani R.Drug-eluting stent and coronary thrombosis:biological mechanisms and clinical implications.Circulation 2007;115(8):1051-1058.
36 Bertrand OF,Sipehia R,Mongrain R,Rodes J,Tardif JC,Bilodeau L,Cote G,Bourassa MG.Biocompatibility aspects of new stent technology.J Am Coll Cardiol 1998;32(3):562-571.
37 Heublein B,Rohde R,Kaese V,Niemeyer M,Hartung W,Haverich A.Biocorrosion of magnesium alloys:a new principle in cardiovascular implant technology?Heart 2003;89(6):651-656.
38 Waksman R,Pakala R,Kuchulakanti PK,Baffour R,Hellinga D,Seabron R,Tio FO,Wittchow E,Hartwig S,Harder C,Rohde R,Heublein B,Andreae A,Waldmann KH,Haverich A.Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries.Catheter Cardiovasc Interv 2006;68(4):607-617;discussion 618-619.
39 Zartner P,Cesnjevar R,Singer H,Weyand M.First successful implantation of a biodegradable metal stent into the left pulmonary artery of a preterm baby.Catheter Cardiovasc Interv 2005;66(4):590-594.
40 Di Mario C,Griffiths H,Goktekin O,Peeters N,Verbist J,Bosiers M,Deloose K,Heublein B,Rohde R,Kasese V,Ilsley C,Erbel R.Drugeluting bioabsorbable magnesium stent.J Interv Cardiol 2004;17(6):391-395.
41 Schranz D,Zartner P,Michel-Behnke I,Akinturk H.Bioabsorbable metal stents for percutaneous treatment of critical recoarctation of the aorta in a newborn.Catheter Cardiovasc Interv 2006;67(5):671-673.
42 Mulla A,Massey KL,Kalra J.Vitreous humor biochemical constituents:evaluation of between-eye differences.Am J Forensic Med Pathol 2005;26(2):146-149.
43 George GA,Heaton FW.Changes in cellular composition during magnesium deficiency.Biochem J 1975;152(3):609-615.
44 Agarwal R,Iezhitsa L,Agarwal P.Pathogenetic role of magnesium deficiency in ophthalmic diseases.Biometals 2013.[Epub ahead of print]
45 Hatwal A,Gujral AS,Bhatia RP,Agrawal JK,Bajpai HS.Association of hypomagnesemia with diabetic retinopathy.Acta Ophthalmol(Copenh)1989;67(6):714-716.
46 Mishima S.Clinical pharmacokinetics of the eye.Proctor lecture.Invest Ophthalmol Vis Sci 1981;21(4):504-541.
47 Kirkpatrick H.The use of magnesium sulphate as a local application in inflammation of the conjunctiva and cornea.Br J Ophthalmol 1920;4(6):281.
48 Bachman WG,Wilson G.Essential ions for maintenance of the corneal epithelial surface.Invest Ophthalmol Vis Sci 1985;26(11):1484-1488.
49 Hogan ZS,Brown KL,Ishola A,Gatimu J,Flucker L,Huff JW.Effects of divalent cations on bovine corneal stromal swelling rates.Curr Eye Res2008;33(8):677-682.
50 Gong H,Amemiya T,Takaya K.Retinal changes in magnesiumdeficient rats.Exp Eye Res 2001;72(1):23-32.
51 Thalasselis A.The possible relationship between keratoconus and magnesium deficiency.Ophthalmic Physiol Opt 2005;25(1):7-12.
52 Andreassen TT,Simonsen AH,Oxlund H.Biomechanical properties of keratoconus and normal corneas.Exp Eye Res 1980;31(4):435-441.
53 Aktekin M,Sargon MF,Cakar P,Celik HH,Firat E.Ultrastructure of the cornea epithelium in keratoconus.Okajimas Folia Anat Jpn 1998;75(1):45-53.
54 Sawaguchi S,Fukuchi T,Abe H,Kaiya T,Sugar J,Yue BY.Threedimensional scanning electron microscopic study of keratoconus corneas.Arch Ophthalmol 1998;116(1):62-68.
55 Pouliquen Y,Graf B,Hamada R,Giraud JP,Offret G.Fibrocytes in keratoconus.Morphological aspect and modification of the extra-cellular space.Study with light and electron microscopy.Arch Ophtalmol Rev Gen Ophtalmol 1972;32(8):571-586.
56 Dilsiz N,Olcucu A,Atas M.Determination of calcium,sodium,potassium and magnesium concentrations in human senile cataractous lenses.Cell Biochem Funct 2000;18(4):259-262.
57 Agarwal R,Iezhitsa I,Agarwal P,Spasov A.Magnesium deficiency:does it have a role to play in cataractogenesis?Exp Eye Res 2012;101:82-89.
58 Agarwal R,Iezhitsa I,Awaludin NA,Ahmad Fisol NF,Bakar NS,Agarwal P,Abdul Rahman TH,Spasov A,Ozerov A,Mohamed Ahmed Salama MS,Mohd Ismail N.Effects of magnesium taurate on the onset and progression of galactose-induced experimental cataract:in vivo and in vitro evaluation.Exp Eye Res 2013;110:35-43.
59 Nagai N,Fukuhata T,Ito Y.Effect of magnesium deficiency on intracellular ATP levels in human lens epithelial cells.Biol Pharm Bull2007;30(1):6-10.
60 Nagai N,Ito Y,Inomata M,Shumiya S,Tai H,Hataguchi Y,Nakagawa K.Delay of cataract development in the Shumiya cataract rat by the administration of drinking water containing high concentration of magnesium ion.Biol Pharm Bull 2006;29(6):1234-1238.
61 Agarwal R,Iezhitsa IN,Agarwal P,Spasov AA.Mechanisms of cataractogenesis in the presence of magnesium deficiency.Magnes Res2013;26(1):2-8.
62 Kao CL,Chou CK,Tsai DC,Hsu WM,Liu JH,Wang CS,Lin JC,Wu CC,Peng CH,Chang CJ,Kao CL,Chiou SH.Nitric oxide levels in the aqueous humor in cataract patients.J Cataract Refract Surg2002;28(3):507-512.
63 Ornek K,Karel F,Buyukbingol Z.May nitric oxide molecule have a role in the pathogenesis of human cataract?Exp Eye Res 2003;76(1):23-27.
64 Retamal MA,Yin S,Altenberg GA,Reuss L.Modulation of Cx46hemichannels by nitric oxide.Am J Physiol Cell Physiol 2009;296(6):C1356-1363.
65 Carafoli E.The Ca2+pump of the plasma membrane.J Biol Chem 1992;267(4):2115-2118.
66 Hulsman CA,Vingerling JR,Hofman A,Witteman JC,de Jong PT.Blood pressure,arterial stiffness,and open-angle glaucoma:the Rotterdam study.Arch Ophthalmol 2007;125(6):805-812.
67 Bonomi L,Marchini G,Marraffa M,Bernardi P,Morbio R,Varotto A.Vascular risk factors for primary open angle glaucoma:the EgnaNeumarkt Study.Ophthalmology 2000;107(7):1287-1293.
68 Leske MC,Heijl A,Hyman L,Bengtsson B,Dong L,Yang Z.Predictors of long-term progression in the early manifest glaucoma trial.Ophthalmology 2007;114(11):1965-1972.
69 Wang M,Tashiro M,Berlin JR.Regulation of L-type calcium current by intracellular magnesium in rat cardiac myocytes.J Physiol2004;555(Pt 2):383-396.
70 Howarth FC,Levi AJ.Internal free magnesium modulates the voltage dependence of contraction and Ca transient in rabbit ventricular myocytes.Pflugers Arch 1998;435(5):687-698.
71 Ishiguro S,Matsuyama T,Sakaguchi H,Nishio A.Ex vivo study of the increased sensitivity to NO of endothelium-denuded thoracic aortas isolated from dietary magnesium-deficient rats.Magnes Res1997;10(1):21-31.
72 Laurant P,Touyz RM.Physiological and pathophysiological role of magnesium in the cardiovascular system:implications in hypertension.J Hypertens 2000;18(9):1177-1191.
73 Teragawa H,Kato M,Yamagata T,Matsuura H,Kajiyama G.Magnesium causes nitric oxide independent coronary artery vasodilation in humans.Heart 2001;86(2):212-216.
74 Barbagallo M,Dominguez LJ,Galioto A,Pineo A,Belvedere M.Oral magnesium supplementation improves vascular function in elderly diabetic patients.Magnes Res 2010;23(3):131-137.
75 Soltani N,Keshavarz M,Sohanaki H,Zahedi Asl S,Dehpour AR.Relaxatory effect of magnesium on mesenteric vascular beds differs from normal and streptozotocin induced diabetic rats.Eur J Pharmacol2005;508(1-3):177-181.
76 Kumar AR,Kurup PA.Inhibition of membrane Na+-K+ATPase activity:a common pathway in central nervous system disorders.J Assoc Physicians India 2002;50:400-406.
77 Sugiyama T,Moriya S,Oku H,Azuma I.Association of endothelin-1with normal tension glaucoma:clinical and fundamental studies.Surv Ophthalmol 1995;39 Suppl 1:S49-S56.
78 Kaiser HJ,Flammer J,Graf T,Stümpfig D.Systemic blood pressure in glaucoma patients.Graefes Arch Clin Exp ophthalmol 1993;231(12):677-680.
79 Winterkorn JM.The influence of magnesium on visual field and peripheral vasospasm in glaucoma.Surv Ophthalmol 1995;40(1):83-84.
80 Mc Menimen KA,Dougherty DA,Lester HA,Petersson EJ.Probing the Mg2+blockade site of an N-methyl-D-aspartate(NMDA)receptor with unnatural amino acid mutagenesis.ACS Chem Biol 2006;1(4):227-234.
81 Mark LP,Prost RW,Ulmer JL,Smith MM,Daniels DL,Strottmann JM,Brown WD,Hacein-Bey L.Pictorial review of glutamate excitotoxicity:fundamental concepts for neuroimaging.AJNR Am J Neuroradiol 2001;22(10):1813-1824.
82 Decollogne S,Tomas A,Lecerf C,Adamowicz E,Seman M.NMDA receptor complex blockade by oral administration of magnesium:comparison with MK-801.Pharmacol Biochem Behav 1997;58(1):261-268.
83 Lambuk L,Jafri AJ,Arfuzir NN,Iezhitsa I,Agarwal R,Rozali KN,Agarwal P,Bakar NS,Kutty MK,Yusof AP,Krasilnikova A,Spasov A,Ozerov A,Ismail NM.Neuroprotective effect of magnesium acetyltaurate against NMDA-induced excitotoxicity in rat retina.Neurotox Res2017;31(1):31-45.
84 Carafoli E.Calcium-a universal carrier of biological signals.Delivered on 3 July 2003 at the Special FEBS Meeting in Brussels.FEBS J2005;272(5):1073-1089.
85 Blaylock RL.Food additive excitotoxins and degenerative brain disorders.Med Sentinel 1999;4:212-215.
86 Sun MH,Pang JH,Chen SL,Han WH,Ho TC,Chen KJ,Kao LY,Lin KK,Tsao YP.Retinal protection from acute glaucoma-induced ischemiareperfusion injury through pharmacologic induction of heme oxygenase-1.Invest Ophthalmol Vis Sci 2010;51(9):4798-4808.
87 Lipton SA,Choi YB,Pan ZH,Lei SZ,Chen HS,Sucher NJ,Loscalzo J,Singel DJ,Stamler JS.A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds.Nature 1993;364(6438):626-632.
88 Suschek CV,Kolb H,Kolb-Bachofen VV.Effects of magnesium dobesilate on nitric oxide synthase activity in endothelial cells.In J Angiol1999;8(5):21-24.
89 Sun X,Mei Y,Tong E.Effect of magnesium on nitric oxide synthase of neurons in cortex during early period of cerebral ischemia.J Tongji Med Univ 2000;20(1):13-15,42.
90 Gaspar AZ,Gasser P,Flammer J.The influence of magnesium on visual field and peripheral vasospasm in glaucoma.Ophthalmologica1995;209(1):11-13.
91 Aydin B,Onol M,Hondur A,Kaya MG,Ozdemir H,Cengel A,Hasanreisoglu B.The effect of oral magnesium therapy on visual field and ocular blood flow in normotensive glaucoma.Eur J Ophthalmol2010;20(1):131-135.
92 Troncoso MU.Cyclodialysis with insertion of a metal implant in the treatment of glaucoma:a preliminary report.Arch Ophthalmol 1940;23(2):270-297.
93 Hoff PHB.Use of troncoso's magnesium implant in cyclodialysis for relief of glaucoma:observations in two cases.Arch Ophthalmol1945;33(5):404-405.
94 Moravej M,Mantovani D.Biodegradable metals for cardiovascular stent application:interests and new opportunities.Int J Mol Sci 2011;12(7):4250-4270.
95 Staiger MP,Pietak AM,Huadmai J,Dias G.Magnesium and its alloys as orthopedic biomaterials:a review.Biomaterials 2006;27(9):1728-1734.
96 Zeng R,Dietzel W,Witte F,Hort N,Blawert C.Progress and challenge for magnesium alloys as biomaterials.Adv Eng Mater 2008;10(8):B3-B14.
97 Joner M,Finn AV,Farb A,Mont EK,Kolodgie FD,Ladich E,Kutys R,Skorija K,Gold HK,Virmani R.Pathology of drug-eluting stents in humans:delayed healing and late thrombotic risk.J Am Coll Crdiol2006;48(1):193-202.
98 Nebeker JR,Virmani R,Bennett CL,Hoffman JM,Samore MH,Alvarez J,Davidson CJ,Mc Koy JM,Raisch DW,Whisenant BK,Yarnold PR,Belknap SM,West DP,Gage JE,Morse RE,Gligoric G,Davidson L,Feldman MD.Hypersensitivity cases associated with drug-eluting coronary stents:a review of available cases from the Research on Adverse Drug Events and Reports(RADAR)project.J Am Coll Crdiol 2006;47(1):175-181.
99 Nordmann AJ,Briel M,Bucher HC.Mortality in randomized controlled trials comparing drug-eluting vs bare metal stents in coronary artery disease:a meta-analysis.Eur Heart J 2006;27(23):2784-2814.
100 Hofma SH,van der Giessen WJ,van Dalen BM,Lemos PA,Mc Fadden EP,Sianos G,Ligthart JM,van Essen D,de Feyter PJ,Serruys PW.Indication of long-term endothelial dysfunction after sirolimuseluting stent implantation.Eur Heart J 2006;27(2):166-170.
101 Erbel R,Di Mario C,Bartunek J,Bonnier J,de Bruyne B,Eberli FR,Erne P,Haude M,Heublein B,Horrigan M,Ilsley C,Bose D,Koolen J,Luscher TF,Weissman N,Waksman R.Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents:a prospective,non-randomised multicentre trial.Lancet 2007;369(9576):1869-1875.